AI vendors make safety claims you can't verify on your own. PsiBench tests their models against the same medication-safety standards your hospital already uses, with no EHR work and no patient data.
Clinical AI is replacing the rule-based decision support your existing CPOE/EHR is audited against. The vendors making those claims are the ones grading them. Hospitals need an evaluation regime that is not commissioned by the vendor.
PsiBench is designed to be useful before any procurement decision, during evaluation, and after deployment, without ever accessing your patients' records.
For any clinical AI product on your shortlist, see the independent three-tier safety score against the medication-safety standard already in use. Compare candidates on the same evaluation, not on each vendor's chosen number.
Evaluate a specific vendor configuration, model, retrieval setup, fine-tunes, against your audit criteria, before going live. Synthetic patient scenarios; no PHI; no integration with your live EHR.
When the vendor updates the model, PsiBench re-runs the same evaluation. A safety regression in the latest version is flagged on the same scorecard your safety committee already understands.
PsiBench evaluations use synthetic patient scenarios authored by clinical pharmacology experts. We never request, access, transmit, or store protected health information. Participating health systems share only configuration parameters and aggregate metrics, never patient records.
Synthetic-first methodology. All scenarios are clinical-pharmacology-authored synthetic patient cases. PHI is never required to participate, evaluate, or subscribe.
Posognos evaluates through the same channels clinicians use, EHR test environments, standard deployment configurations, vendor API endpoints. Your IT roadmap is not on the critical path.
The first benchmark is built on the national medication-safety standard used to audit 2,000+ U.S. hospitals. Results are immediately interpretable by your existing safety committee.
PsiBench is being built with leading U.S. and international institutions: academic medical centers, large integrated health systems, national pharmacy and safety bodies, and ministries of health. Each contributor reviews scenarios in their domain.
A formal announcement of the founding cohort is forthcoming. Health systems and standards bodies that want to help define how clinical AI is evaluated are invited to join now, ahead of public launch.
Whether you're evaluating clinical AI procurement, sitting on a safety committee, or looking to contribute as a validation network member.